Needleless CGM: Smart Contact Lens, Dexcom G8 & Non-Invasive Glucose Monitors (2026)

Diabetes Technology · 6 · February 11, 2026

Imagine checking your blood sugar by blinking. No fingerstick. No sensor patch on your arm. No needle going under your skin. Just a contact lens sitting on your eye, reading glucose from your tears and sending the number to your phone.

Samsung Health and Novartis announced a glucose-sensing smart contact lens in March 2026. It is in Phase I trials. It is not on the market yet. But it represents a future that millions of diabetes patients have been waiting for: truly needleless, truly painless, truly continuous glucose monitoring.

How a Contact Lens Reads Glucose

Tear fluid contains glucose at concentrations roughly 30–50% of blood glucose levels. The lag time between blood glucose changes and tear glucose changes is approximately 5–15 minutes — faster than the interstitial fluid used by current CGMs like Libre and Dexcom (which have a 5–10 minute lag themselves).

The Samsung lens embeds a tiny biosensor, a miniature antenna, and a wireless power receiver into a standard soft contact lens. The sensor uses glucose oxidase — the same enzyme chemistry that fingerstick test strips have used for decades — but miniaturised onto a transparent film. An NFC-like signal powers the sensor and transmits readings to a nearby phone.

The engineering challenge is enormous: the sensor must be biocompatible, transparent, comfortable for all-day wear, accurate across the full glucose range, and survive being in contact with the eye's surface. Google attempted this in 2014 and abandoned the project. Samsung and Novartis believe materials science has caught up.

Non-Invasive CGMs Already Getting Close

The contact lens is not the only approach. Several non-invasive glucose monitoring technologies are in late-stage development:

Dexcom G8 (approved January 2026): Still uses a subcutaneous sensor, but the needle is 40% smaller and the sensor lasts 30 days instead of 10. It also monitors ketones — a first for any CGM. Not needleless, but dramatically less invasive than previous generations.

Optical/NIR spectroscopy wearables: Companies like Glucowise and Nemaura Medical are developing wristband devices that shine near-infrared light through the skin and measure glucose by analysing how the light is absorbed. No needle penetration. The accuracy challenge: skin thickness, hydration, and melanin levels all interfere with readings.

Radiofrequency sensing: Know Labs' Bio-RFID technology uses radio waves to identify glucose molecules through the skin. Their KnowU device received FDA Breakthrough Device designation. Accuracy is improving but not yet CGM-equivalent.

Sweat-based patches: Glucose appears in sweat at measurable concentrations. Flexible adhesive patches with embedded biosensors can read it — but sweat production is intermittent and exercise-dependent, making continuous monitoring difficult.

What You Can Use Today

Until needleless CGMs reach the market, the least invasive option is the Dexcom G7 or Freestyle Libre 3 — both use a thin filament (not a traditional needle) inserted with an auto-applicator. Most patients describe the insertion as painless. The sensor is the size of two stacked coins and stays on for 10–14 days.

Journey for Health's CGM Monitor connects to both Libre and Dexcom via Bluetooth or cloud API. When needleless CGMs arrive, the platform will integrate them the same way — your historical data, trends, and predictions carry forward regardless of which hardware you wear.

The Timeline

Samsung's contact lens: Phase I trials in 2026, earliest commercial availability 2028–2029. Dexcom G8 (30-day sensor): available now in select markets. Know Labs Bio-RFID: FDA submission expected late 2026. Optical wristbands: multiple devices in clinical trials, none FDA-cleared for diabetes management.

Track which devices are compatible with Journey for Health (jforh.com) at CGM Monitor and follow new device announcements at Diabetes Breakthroughs.